PURINE & PYRIMIDINE
METABOLISM & DISORDERS
By
DR KHALED SALEH ALGARIRi
2014
FUNCTIONS OF NUCLEOTIDES
Polymerize to make DNA and RNA
Energy currency of the cell e.g. ATP, GTP
Act as carriers of active intermediates in various
metabolic pathways e.g. UDP-glucose in glycogen
synthesis, SAM
Component of coenzymes e.g. FAD, NADH, NADPH
Act as 2nd messengers e.g. cAMP and cGMP
Allosteric regulation of various metabolic pathways e.g.
ATP inhibits PFK-1
There are two pathways leading to
nucleotides
De novo synthesis: The synthesis of nucleotides
begins with their metabolic precursors: amino
acids, ribose-5-phosphate, CO2, and one-carbon
units.
Salvage pathways: The synthesis of nucleotide
by recycle the free bases or nucleosides released
from nucleic acid breakdown.
Once formed, IMP is rapidly converted to AMP
and GMP (it does not accumulate in cells).
IMP Synthesis - Significance
IMP = serves as a precursor for synthesis of all
other purine nucleotides such as adenine and
guanosine monophosphate (AMP & GMP)and
ATP.
Salvage Pathways for Purine Synthesis
Purine bases created by degradation of RNA and DNA
and intermediate of purines synthesis can be directly
converted to the corresponding nucleotides.
The significant of salvage pathway
1- Save fuel
2- Some tissues and organs such as brain and bone marrow
are only capable of synthesizing nucleotides by Salvage
pathways
Broken down endogenous nucleotides = salvage pathways.
Purine salvage pathways us one of two enzymes.
Adenine phosphoribosyltransferase (APRT).
Converts free adenine to AMP
Hypoxanthine-guanine phosphoribosultransferase
(HGPRT).
Converts hypoxanthine to IMP
Converts guanine to GMP
Purine Salvage Pathway
N
NN
N
NH2
O
Guanine
N
N N
O
N
Hypoxanthine
O
OHHO
2-O3POH2C
N
N N
O
N
IMP
O
OHHO
2-O3POH2C
N
NN
N
NH2
O
GMP
.
.
Adenine AMP
PRPP PPi
adenine
phosphoribosyl transferase
PRPP PPi
hypoxanthine-guanine
phosphoribosyl transferase
(HGPRT)
Absence of activity of HGPRT leads to Lesch-Nyhan syndrome.
INOSINE 5’- MONOPHOSPHATE (IMP)
GMP
synthetase
ATP + Gln
AMP + Glu
Guanosine
monophosphate (GMP)
Fumarate
Adenylosuccinase
Adenosine
monophosphate (AMP)
Adenylosuccinate
GTP + Asp
GDP + Pi
Adenylosuccinate
synthetase
NAD+
NADH
IMP
dehydrogenase
Xanthine monophosphate
(XMP)
DEGRADATION OF PURINE NUCLEOTIDES
Guanase
NH3
Xanthine
Xanthine
oxidase
Guanine
Ribose
5’ Phosphorylase
Ribose
Hypoxanthine
Uric Acid
(excreted)
Xanthine
oxidase
Adenosine
deaminase
IMPAMP deaminase
AMP GMP
Guanosine
Pi5’ NucleotidasePi
Inosine
Pi
Adenosine
5’ Nucleotidase
IMP is the precursor for both AMP and GMP
DISEASES ASSOCIATED WITH DEFECTS IN
PURINE METABOLISM
HYPERURICEMIA
GOUT
LESCH-NYHAN SYNDROME
KIDNEY STONES
SEVERE COMBINED
IMMUNODEFECIENCY (SCID)
HYPERURICEMIA
Characterized by plasma urate (uric acid) level
greater than 7.0 mg/dL
Normal plasma levels
Females = 2.4 - 6 mg/dL
Males = 3.4 - 7 mg/dL
HYPERURICEMIA
•Primary Hyperuricemia: an innate
defect in purine metabolism and/or uric
acid excretion
•Secondary Hyperuricemia: increased
availability of purines due to medications/
medical conditions or through diet.
GOUT
Gout is caused by
precipitation of sodium urate
crystals in the joints resulting
in inflammation and pain.
Progression of Hyperuricemia to Gout
Stage 1: Asymptomatic hyperuricemia. At a serum urate
concentration greater than 6.8 mg/dL, urate crystals may start to
deposit in the joints. No evidence that treatment is required.
Stages 2 : Acute gout. If sufficient urate deposits develop around
joints, and if the local environment or some trauma triggers the
release of crystals into the joint space, an inflammatory response
occurs. These flares can be self-resolving but are likely to recur.
Stage 3: Intercritical periods. These are the intervals between
attacks. During these periods, crystals may still be present at a low
level in the synovial tissue and fluid, resulting in future attacks.
Stage 4: Advanced gout. If crystal deposits continue to
accumulate, patients may develop chronically stiff, swollen joints
and tophi. This advanced stage of gout is relatively uncommon
generally avoidable with therapy.
Underexcretion of uric acid
Diet rich in purines/alcohol; deficient in dairy products
Increased purine degradation
Increased PRPP Synthetase activity
overproduction of PRPP = increased purine synthesis =
increased purine degradation = increased uric acid production
Decreased/partial HGPRT activity
1) Deficiency of HGPRT = increased HX and G
2) Deficiency of HGPRT = accumulation of PRPP =
increased purine synthesis = increased uric acid
levels
3) Deficiency of HGPRT = decreased IMP and
GMP = decreased inhibitors for purine synthesis
GOUT - Causes
Colchicine –reduces inflammation
Allopurinol – inhibits uric acid synthesis
Low purine diet - Foods that are high in purine
include:
Red meat and organ meats (eg. liver)
Yeasts and yeast extracts (eg. beer and alcoholic beverages)
Asparagus, spinach, beans, peas, lentils, oatmeal, cauliflower
and mushrooms
Avoid caffeine and alcohol
Keep hydrated
GOUT - Treatment
HN
HC
N
C
C
C
N
H
CH
N
O
Hypoxanthine
HN
HC
N
C
C
C
N
H
N
H
C
O
Allopurinol
Allopurinol – a suicide inhibitor used to treat Gout
Xanthine oxidase
Xanthine oxidase
Gout:
accumula-tion
of uric acid
salts in joints
Gout: accumulation of
uric acid salts in joints
Gout: tophuses –
accumulation of uric
acid salts in
cartilages, under
skin.
KIDNEY STONES
When uric acid is present in
high concentrations in the
blood, it may precipitate as a
salt in the kidneys. The salt can
form stones, which can in turn
cause pain, infection, and
kidney damage.
Gout: kidney stones.
Lesch-Nyhan Syndrom: is a inherited disorder caused by a deficiency
of the enzyme hypoxanthine-guanine phosphoribosyltransferase. LNS is
present at birth in baby boys.
Hypoxanthine and guanine are not used in the salvage pathway of purine
nucleotides synthesis.
Hypoxanthine and guanine are not utilizied repeatedly but converted into
uric acid.
Symptoms:
- severe gout
-severe mental and physical problems
- self-mutilating behaviors
SEVERE COMBINED IMMUNODEFICIENCY
(SCID)
Adenosine deaminase deficiency
Accumulation of dATP = inhibition of ribonucleotide
reductase =B and T cells unable to divide
Pyrimidine Ribonucleotide Synthesis
Uridine Monophosphate (UMP) is synthesized first
CTP is synthesized from UMP
Pyrimidine ring synthesis completed first; then
attached to ribose-5-phosphate
N1, C4, C5, C6 : Aspartate
C2 : HCO3
-
N3 : Glutamine amide Nitrogen
2 ATP + HCO3
-
+ Glutamine + H2O
CO
O PO3
-2
NH2
Carbamoyl Phosphate
NH2
C
N
H
CH
CH2
C
COO
O
HO
O
Carbamoyl Aspartate
HN
C
N
H
CH
CH2
C
COO
O
O
Dihydroorotate
HN
C
N
H
C
CH
C
COO
O
O
Orotate
HN
C
N
C
CH
C
COO
O
O
HH
CH2
OH OH
H H
O
O2-
O3P

Orotidine-5'-monophosphate
(OMP)
HN
C
N
CH
CH
C
O
O
HH
CH2
OH OH
H H
O
O2-
O3P

Uridine Monophosphate
(UMP)
2 ADP +
Glutamate +
Pi
Carbamoyl
Phosphate
Synthetase II
Aspartate
Transcarbamoylase
(ATCase)
Aspartate
Pi
H2O
Dihydroorotase
Quinone
Reduced
Quinone
Dihydroorotate
Dehydrogenase
PRPP PPi
Orotate Phosphoribosyl
Transferase
CO2
OMP
Decarboxylase
Pyrimidine Synthesis
UMP  UTP and CTP
Nucleoside monophosphate kinase catalyzes
transfer of Pi to UMP to form UDP; nucleoside
diphosphate kinase catalyzes transfer of Pi from
ATP to UDP to form UTP
CTP formed from UTP via CTP Synthetase
driven by ATP hydrolysis
Glutamine provides amide nitrogen for C4 in animals
UTP and CTP biosynthesis
UDP
ADP
UTP
ATP ADP
UMP
ATP
kinase kinase
Degradation of Pyrimidines
CMP and UMP degraded to bases similarly to purines
by
Dephosphorylation
Deamination
Glycosidic bond cleavage
Uracil reduced in liver, forming -alanine
Converted to malonyl-CoA  fatty acid synthesis for
energy metabolism
OROTACIDURIA
inherited disorder of pyrimidine synthesis
caused by a deficiency of the enzyme of
orotate-phosphoribosyltransferase and
decarboxylase.
Symptoms:
–excess of orotic acid and its excretion with
urine (1.0-1.5 g)
-mental and physical retardation
-megaloblastic anemia
– Treatment: patients are fed uridine
U  UMP  UDP  UTP
UTP inhibits carbamoyl phosphate synthase II, preventing the
biosynthesis and accumulation of orotic acid
O
OHOH
CH2
O
P
O
P
O
-O
-O
O-
-
O3PO
O
C
NH
O
HN
COOC
C
H
C
O
PPi
Orotate 5-phosphoribosyl-1-pyrophosphate (PRPP)
THANK YOU

Purine & pyrimidine metabolism and disorders

  • 1.
    PURINE & PYRIMIDINE METABOLISM& DISORDERS By DR KHALED SALEH ALGARIRi 2014
  • 2.
    FUNCTIONS OF NUCLEOTIDES Polymerizeto make DNA and RNA Energy currency of the cell e.g. ATP, GTP Act as carriers of active intermediates in various metabolic pathways e.g. UDP-glucose in glycogen synthesis, SAM Component of coenzymes e.g. FAD, NADH, NADPH Act as 2nd messengers e.g. cAMP and cGMP Allosteric regulation of various metabolic pathways e.g. ATP inhibits PFK-1
  • 3.
    There are twopathways leading to nucleotides De novo synthesis: The synthesis of nucleotides begins with their metabolic precursors: amino acids, ribose-5-phosphate, CO2, and one-carbon units. Salvage pathways: The synthesis of nucleotide by recycle the free bases or nucleosides released from nucleic acid breakdown.
  • 4.
    Once formed, IMPis rapidly converted to AMP and GMP (it does not accumulate in cells).
  • 5.
    IMP Synthesis -Significance IMP = serves as a precursor for synthesis of all other purine nucleotides such as adenine and guanosine monophosphate (AMP & GMP)and ATP.
  • 6.
    Salvage Pathways forPurine Synthesis Purine bases created by degradation of RNA and DNA and intermediate of purines synthesis can be directly converted to the corresponding nucleotides. The significant of salvage pathway 1- Save fuel 2- Some tissues and organs such as brain and bone marrow are only capable of synthesizing nucleotides by Salvage pathways Broken down endogenous nucleotides = salvage pathways. Purine salvage pathways us one of two enzymes. Adenine phosphoribosyltransferase (APRT). Converts free adenine to AMP Hypoxanthine-guanine phosphoribosultransferase (HGPRT). Converts hypoxanthine to IMP Converts guanine to GMP
  • 7.
    Purine Salvage Pathway N NN N NH2 O Guanine N NN O N Hypoxanthine O OHHO 2-O3POH2C N N N O N IMP O OHHO 2-O3POH2C N NN N NH2 O GMP . . Adenine AMP PRPP PPi adenine phosphoribosyl transferase PRPP PPi hypoxanthine-guanine phosphoribosyl transferase (HGPRT) Absence of activity of HGPRT leads to Lesch-Nyhan syndrome.
  • 8.
    INOSINE 5’- MONOPHOSPHATE(IMP) GMP synthetase ATP + Gln AMP + Glu Guanosine monophosphate (GMP) Fumarate Adenylosuccinase Adenosine monophosphate (AMP) Adenylosuccinate GTP + Asp GDP + Pi Adenylosuccinate synthetase NAD+ NADH IMP dehydrogenase Xanthine monophosphate (XMP)
  • 9.
    DEGRADATION OF PURINENUCLEOTIDES Guanase NH3 Xanthine Xanthine oxidase Guanine Ribose 5’ Phosphorylase Ribose Hypoxanthine Uric Acid (excreted) Xanthine oxidase Adenosine deaminase IMPAMP deaminase AMP GMP Guanosine Pi5’ NucleotidasePi Inosine Pi Adenosine 5’ Nucleotidase IMP is the precursor for both AMP and GMP
  • 10.
    DISEASES ASSOCIATED WITHDEFECTS IN PURINE METABOLISM HYPERURICEMIA GOUT LESCH-NYHAN SYNDROME KIDNEY STONES SEVERE COMBINED IMMUNODEFECIENCY (SCID)
  • 11.
    HYPERURICEMIA Characterized by plasmaurate (uric acid) level greater than 7.0 mg/dL Normal plasma levels Females = 2.4 - 6 mg/dL Males = 3.4 - 7 mg/dL
  • 12.
    HYPERURICEMIA •Primary Hyperuricemia: aninnate defect in purine metabolism and/or uric acid excretion •Secondary Hyperuricemia: increased availability of purines due to medications/ medical conditions or through diet.
  • 13.
    GOUT Gout is causedby precipitation of sodium urate crystals in the joints resulting in inflammation and pain.
  • 14.
    Progression of Hyperuricemiato Gout Stage 1: Asymptomatic hyperuricemia. At a serum urate concentration greater than 6.8 mg/dL, urate crystals may start to deposit in the joints. No evidence that treatment is required. Stages 2 : Acute gout. If sufficient urate deposits develop around joints, and if the local environment or some trauma triggers the release of crystals into the joint space, an inflammatory response occurs. These flares can be self-resolving but are likely to recur. Stage 3: Intercritical periods. These are the intervals between attacks. During these periods, crystals may still be present at a low level in the synovial tissue and fluid, resulting in future attacks. Stage 4: Advanced gout. If crystal deposits continue to accumulate, patients may develop chronically stiff, swollen joints and tophi. This advanced stage of gout is relatively uncommon generally avoidable with therapy.
  • 15.
    Underexcretion of uricacid Diet rich in purines/alcohol; deficient in dairy products Increased purine degradation Increased PRPP Synthetase activity overproduction of PRPP = increased purine synthesis = increased purine degradation = increased uric acid production Decreased/partial HGPRT activity 1) Deficiency of HGPRT = increased HX and G 2) Deficiency of HGPRT = accumulation of PRPP = increased purine synthesis = increased uric acid levels 3) Deficiency of HGPRT = decreased IMP and GMP = decreased inhibitors for purine synthesis GOUT - Causes
  • 16.
    Colchicine –reduces inflammation Allopurinol– inhibits uric acid synthesis Low purine diet - Foods that are high in purine include: Red meat and organ meats (eg. liver) Yeasts and yeast extracts (eg. beer and alcoholic beverages) Asparagus, spinach, beans, peas, lentils, oatmeal, cauliflower and mushrooms Avoid caffeine and alcohol Keep hydrated GOUT - Treatment
  • 17.
    HN HC N C C C N H CH N O Hypoxanthine HN HC N C C C N H N H C O Allopurinol Allopurinol – asuicide inhibitor used to treat Gout Xanthine oxidase Xanthine oxidase
  • 19.
  • 20.
    Gout: accumulation of uricacid salts in joints
  • 21.
    Gout: tophuses – accumulationof uric acid salts in cartilages, under skin.
  • 22.
    KIDNEY STONES When uricacid is present in high concentrations in the blood, it may precipitate as a salt in the kidneys. The salt can form stones, which can in turn cause pain, infection, and kidney damage.
  • 23.
  • 24.
    Lesch-Nyhan Syndrom: isa inherited disorder caused by a deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase. LNS is present at birth in baby boys. Hypoxanthine and guanine are not used in the salvage pathway of purine nucleotides synthesis. Hypoxanthine and guanine are not utilizied repeatedly but converted into uric acid. Symptoms: - severe gout -severe mental and physical problems - self-mutilating behaviors
  • 25.
    SEVERE COMBINED IMMUNODEFICIENCY (SCID) Adenosinedeaminase deficiency Accumulation of dATP = inhibition of ribonucleotide reductase =B and T cells unable to divide
  • 26.
    Pyrimidine Ribonucleotide Synthesis UridineMonophosphate (UMP) is synthesized first CTP is synthesized from UMP Pyrimidine ring synthesis completed first; then attached to ribose-5-phosphate N1, C4, C5, C6 : Aspartate C2 : HCO3 - N3 : Glutamine amide Nitrogen
  • 27.
    2 ATP +HCO3 - + Glutamine + H2O CO O PO3 -2 NH2 Carbamoyl Phosphate NH2 C N H CH CH2 C COO O HO O Carbamoyl Aspartate HN C N H CH CH2 C COO O O Dihydroorotate HN C N H C CH C COO O O Orotate HN C N C CH C COO O O HH CH2 OH OH H H O O2- O3P  Orotidine-5'-monophosphate (OMP) HN C N CH CH C O O HH CH2 OH OH H H O O2- O3P  Uridine Monophosphate (UMP) 2 ADP + Glutamate + Pi Carbamoyl Phosphate Synthetase II Aspartate Transcarbamoylase (ATCase) Aspartate Pi H2O Dihydroorotase Quinone Reduced Quinone Dihydroorotate Dehydrogenase PRPP PPi Orotate Phosphoribosyl Transferase CO2 OMP Decarboxylase Pyrimidine Synthesis
  • 28.
    UMP  UTPand CTP Nucleoside monophosphate kinase catalyzes transfer of Pi to UMP to form UDP; nucleoside diphosphate kinase catalyzes transfer of Pi from ATP to UDP to form UTP CTP formed from UTP via CTP Synthetase driven by ATP hydrolysis Glutamine provides amide nitrogen for C4 in animals
  • 29.
    UTP and CTPbiosynthesis UDP ADP UTP ATP ADP UMP ATP kinase kinase
  • 30.
    Degradation of Pyrimidines CMPand UMP degraded to bases similarly to purines by Dephosphorylation Deamination Glycosidic bond cleavage Uracil reduced in liver, forming -alanine Converted to malonyl-CoA  fatty acid synthesis for energy metabolism
  • 31.
    OROTACIDURIA inherited disorder ofpyrimidine synthesis caused by a deficiency of the enzyme of orotate-phosphoribosyltransferase and decarboxylase. Symptoms: –excess of orotic acid and its excretion with urine (1.0-1.5 g) -mental and physical retardation -megaloblastic anemia
  • 32.
    – Treatment: patientsare fed uridine U  UMP  UDP  UTP UTP inhibits carbamoyl phosphate synthase II, preventing the biosynthesis and accumulation of orotic acid O OHOH CH2 O P O P O -O -O O- - O3PO O C NH O HN COOC C H C O PPi Orotate 5-phosphoribosyl-1-pyrophosphate (PRPP)
  • 33.